Hongjun Hao

Hongjun Hao

Auto-generated profile, based on publicly available information

Hongjun Hao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Theranostics
Verified
Journal Article
Open access
DWDaji Wang
Daji Wang
HDHongxia Duan
Hongxia Duan
JFJing Feng
Jing Feng
JXJianquan Xiang
Jianquan Xiang
LFLiqun Feng
Liqun Feng
XYXiyun Yan
Xiyun Yan
The blood-brain barrier (BBB) dysfunction is an initial event of various neuroinflammatory diseases. However, the absence of reliable markers and mechanisms for BBB damage greatly limits the diagnosis and treatment of neuroinflammatory diseases. Soluble CD146 (sCD146) is mainly derived from vascular endothelial cells (ECs) and highly elevated in inflammatory settings. Based on a small cohort, our previous study showed that sCD146 is elevated in the cerebrospinal fluid (CSF) of multiple sclerosis (MS), which is accompanied with BBB damage. Nevertheless, whether sCD146 monitors and regulates the BBB dysfunction remains unknown.

1 April 2023 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
HJHaiqiang Jin
Haiqiang Jin
QLQianshuo Lu
Qianshuo Lu
FGFeng Gao
Feng Gao
HHHongjun Hao
Hongjun Hao
Review Article Application of oligoclonal bands and other cerebrospinal fluid variables in multiple sclerosis and other neuroimmunological diseases: a narrative review Haiqiang Jin, Qianshuo Lu, Feng Gao, Hongjun Hao

1 July 2016 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
JLJing-Jing Luo
Jing-Jing Luo
HLHe Lv
He Lv
WSWei Sun
Wei Sun
JZJuan Zhao
Juan Zhao
HHHong-Jun Hao
Hong-Jun Hao
YHYining Huang
Yining Huang

1 June 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
FGFeng Gao
Feng Gao
GLGang Lin
Gang Lin
YYYun Yuan
Yun Yuan
YHYining Huang
Yining Huang
HHHongjun Hao
Hongjun Hao
LWLing Wang
Ling Wang

21 August 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YYYujing Yuan
Yujing Yuan
YZYawen Zhao
Yawen Zhao
FLFan Li
Fan Li
CLChen Ling
Chen Ling
YWYuan Wu
Yuan Wu
WZWei Zhang
Wei Zhang
Objectives: The aim of this study is to explore the expression of inflammatory cytokines (ICs) in Fabry disease (FD), the correlation between ICs and FD phenotypes, and the impact of enzyme replacement therapy (ERT) on IC expression.Methods: We recruited 67 FD patients and 44 healthy controls (HCs) and detected concentrations of the following ICs: interferon-γ, interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12P70, IL-17A, IL-17F, IL-22, tumor necrosis factor (TNF)-α, and TNF-β. We also analyzed the impact of ERT on IC expression in FD patients and the relationship between IC expression and sex, genotype, phenotype, disease burden, and biomarkers.Results: Most ICs were significantly higher in FD patients than in HCs. A number of ICs were positively correlated with clinical aspects, including disease burden (Mainz Severity Score Index [MSSI]) and cardiac and renal markers. IL-8 was higher in the high MSSI (P-adj=0.026*) than in the low MSSI.Conclusions: ICs were upregulated in FD patients, indicating the role of the innate immune process in FD etiology. ERT ameliorated FD-related inflammatory activation, at least to some extent. IC expression was positively correlated with disease burden and clinical markers in FD. Our findings indicated that the inflammatory pathway may be a promising therapeutic target for FD.

11 March 2023 in Clinical Immunology
Verified
Journal Article
Closed access
HZHaoting Zhan
Haoting Zhan
LCLinlin Cheng
Linlin Cheng
XWXiaoou Wang
Xiaoou Wang
HJHaiqiang Jin
Haiqiang Jin
YLYongmei Liu
Yongmei Liu
YLYongzhe Li
Yongzhe Li